Products
Frexalimab Biosimilar Monoclonal Antibody (CD40L) for Research
Cat No.: GMP-Bios-INN-1209
Anti-CD40LG/CD154 therapeutic antibody (Pre-made Frexalimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Frexalimab (development code INX 021) is a monoclonal antibody targeting CD40LG. It is developed by Sanofi for Systemic lupus erythematosus, Multiple sclerosis, Sjogren's syndrome in Phase III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1209-1mg | 1mg | 3090 |
| GMP-Bios-INN-1209-10mg | 10mg | |
| GMP-Bios-INN-1209-100mg | 100mg | |
| GMP-Bios-INN-1209-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Frexalimab biosimilar, Whole mAb, Anti-CD40LG/CD154 Antibody: Anti-CD40LG/CD154/CD40 ligand/CD40-L therapeutic antibody |
| INN Name | Frexalimab |
| Target | CD40LG/CD154 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2022 |
| Companies | Sanofi |
| Conditions Approved | na |
| Conditions Active | Systemic lupus erythematosus;Multiple sclerosis;Sjogren's syndrome |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
